Table 3.
List of anti-TIGIT trials registered in other solid tumors
| ClinicalTrials.gov identifier | Status | Tumor type | Setting | Phase | Treatment cohorts | Target | Biomarker selection |
|---|---|---|---|---|---|---|---|
| NCT04693234 | Active, not recruiting | Cervical | Metastatic | II | Tislelizumab + ociperlimab Tislelizumab |
PD-1 TIGIT |
|
| NCT03119428 | Terminated | Multicancer | Metastatic | I | OMP-313M32 + nivolumab Nivolumab |
TIGIT PD-1 |
|
| NCT04353830 | Recruiting | Multicancer | Metastatic | I | IBI939 IBI939 + sintilimab |
TIGIT PD-1 |
|
| NCT05102214 | Recruiting | Multicancer | Metastatic | I/II | HLX301 | TIGIT/PD-L1 bispecific | PD-L1 positive in some localizations |
| NCT05061628 | Recruiting | Multicancer | Metastatic | I | JS006 JS006 + toripalimab |
TIGIT PD-1 |
|
| NCT04570839 | Recruiting | Multicancer | Metastatic | I/II | COM701 + BMS-986207 + nivolumab | PVRIG TIGIT PD-1 |
PVRL2 high |
| NCT04047862 | Recruiting | Multicancer | Metastatic | I | Ociperlimab + tislelizumab Ociperlimab + tislelizumab + chemotherapy |
TIGIT PD-1 |
PD-L1 positive in some localizations |
| NCT04354246 | Recruiting | Multicancer | Metastatic | I | COM902 COM902 + COM701 |
TIGIT PVRIG |
|
| NCT05120375 | Recruiting | Multicancer | Metastatic | I | BAT6021 | TIGIT | |
| NCT05417321 | Recruiting | Multicancer | Metastatic | I/II | HB0036 | TIGIT/PD-L1 bispecific | PD-L1 positive |
| NCT05073484 | Recruiting | Multicancer | Metastatic | I | BAT6021 BAT6021 + BAT1308 |
TIGIT PD-1 |
|
| NCT04457778 | Recruiting | Multicancer | Metastatic | I | M6223 M6223 + bintrafusp alfa |
TIGIT Anti-PD-L1/TGF-β Trap |
|
| NCT05394168 | Recruiting | Multicancer | Metastatic | I | HLX53 | TIGIT | |
| NCT05253105 | Withdrawn | Multicancer | Metastatic | I | TAB006 + toripalimab | TIGIT PD-1 |
|
| NCT03628677 | Active, not recruiting | Multicancer | Metastatic | I | Domvanalimab Domvanalimab + zimberelimab |
TIGIT PD-1 |
|
| NCT05060432 | Recruiting | Multicancer | Metastatic | I/II | EOS-448 EOS-448 + pembrolizumab EOS-448 + inupadenant EOS-448 + dostarlimab Inupadenant + dostarlimab EOS-448 + inupadenant + dostarlimab EOS-448 + dostarlimab + chemotherapy EOS-448 + dostarlimab |
TIGIT PD-1 A2aR |
PD-L1 positive in some localizations |
| NCT04150965 | Recruiting | Myeloma | Refractory | I/II | BMS-986016 BMS-986016 + chemotherapy BMS-986207 BMS-986207 + chemotherapy |
LAG-3 TIGIT |
|
| NCT05289492 | Recruiting | Myeloma | Refractory | I/II | EOS884448 EOS884448 + chemotherapy |
TIGIT | |
| NCT05329766 | Recruiting | Gastric | Metastatic | II | Zimberelimab + domvanalimab + chemotherapy Zimberelimab + domvanalimab |
TIGIT PD-1 |
|
| NCT04933227 | Active, not recruiting | Gastric | Metastatic | II | Atezolizumab + tiragolumab + chemotherapy | PD-L1 TIGIT |
|
| NCT05251948 | Active, not recruiting | Gastric | Metastatic | I/II | Atezolizumab + tiragolumab + chemotherapy Atezolizumab + chemotherapy |
PD-L1 TIGIT |
|
| NCT04543617 | Recruiting | Esophageal | Metastatic | III | Atezolizumab + tiragolumab | PD-L1 TIGIT |
|
| NCT04732494 | Recruiting | Esophageal | Metastatic | II | Tislelizumab + ociperlimab Tislelizumab |
PD-1 TIGIT |
PD-L1 ≥10% |
| NCT03708224 | Recruiting | Head and neck | Neoadjuvant | II | Atezolizumab Atezolizumab + tiragolumab Atezolizumab + tocilizumab |
PD-L1 TIGIT IL-6 |
|
| NCT05026606 | Recruiting | Ovarian | Refractory | II | Etiglimab Nivolumab |
TIGIT PD-1 |
|
| NCT05009069 | Recruiting | Rectal | Neoadjuvant | II | Atezolizumab + tiragolumab + chemoradiotherapy Atezolizumab + chemoradiotherapy |
PD-L1 TIGIT |
|
| NCT05023109 | Recruiting | Biliary tract | Metastatic | II | Tislelizumab + ociperlimab + chemotherapy | PD-1 TIGIT |
|
| NCT05019677 | Withdrawn | Biliary tract | Metastatic | II | Tislelizumab + ociperlimab + chemotherapy | PD-1 TIGIT |
|
| NCT05130177 | Recruiting | Melanoma | Metastatic | II | Zimberelimab + domvanalimab | PD-1 TIGIT |
|
| NCT05394337 | Not yet recruiting | Bladder | Neoadjuvant | I | Atezolizumab + tiragolumab | PD-L1 TIGIT |
|
| NCT05327530 | Recruiting | Bladder | Metastatic | II | Avelumab Avelumab + sacituzumab govitecan Avelumab + M6223 Avelumab + NKTR-255 |
PD-L1 TROP2 TIGIT IL-15 |
|
| NCT04656535 | Recruiting | Glioblastoma | Refractory | I | AB122 AB154 AB122 + AB154 |
PD-1 TIGIT |
IL, interleukin; LAG-3, lymphocyte-activation gene 3; PD-1, programmed cell death protein 1; PD-L1, programmed death-ligand 1; PVRIG, poliovirus receptor-related immunoglobulin domain-containing; PVRL2, Poliovirus receptor-related 2; TGF-β, transforming growth factor-beta; TIGIT, T-cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domains; TROP2, trophoblast antigen 2.